|Day's Range||104.25 - 104.25|
|52 Week Range||97.55 - 105.00|
|PE Ratio (TTM)||66.44|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Merck & Co., Inc. (MRK) announced that a large late-stage cardiovascular outcomes study (REVEAL) evaluating anacetrapib, a cholesterol-lowering medicine, met the primary endpoint by reducing cardiovascular (CV) risk.
Global businesses, including Merck, Maersk and Rosneft, reported significant cyberattacks against their computer systems that experts said was ransomware.
Find out which of these pharmaceutical stocks is the best pick right now.